Full-Time

Principal Scientist

Early Clinical Development, Respiratory Therapeutic Area

Deadline 8/31/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$260.3k - $409.7k/yr

+ Annual bonus + Long-term incentive

H1B Sponsorship Available

Boston, MA, USA

Remote

Domestic relocation support is indicated. Travel is expected approximately 25%.

PhD, MD

Category
Biology & Biotech (1)
Required Skills
Biostatistics
Pharmacology

Get referred to Merck

See people who can refer or advise you

Requirements
  • A doctoral degree, specifically an MD or MD/PhD or international equivalent, is required.
  • Experience in biomedical research with a demonstrated record of scientific scholarship and achievement, including scientific publications, is required.
  • Strong interpersonal, writing, and presentation skills and the ability to function in a team environment are required.
  • Experience in clinical medicine, including completion or anticipated completion of residency and fellowship training, is required.
  • Fellowship training and clinical board certification in Pulmonology or a related discipline involving care of respiratory diseases, such as Allergy, are required.
Responsibilities
  • Work with basic science teams on specific diseases and therapeutic areas, providing clinical expertise for identification and validation of novel targets, including designing preclinical and clinical experiments to validate targets or pathways and leveraging this work for development of novel therapeutics.
  • Work with cross-functional teams including discovery scientists, pharmacologists, toxicologists, and other specialists to advance novel therapeutics from preclinical development into clinical development.
  • Serve as a key member and leader of an early development team, collaborating with internal and external staff and scientists across discovery research, biostatistics, drug metabolism, modeling and simulation, regulatory affairs, and global clinical trial operations to design and execute early clinical development strategy.
  • Lead the development and execution of clinical pharmacology studies for programs in Phases I through IV, including formulation or device changes, drug-drug interaction studies, and studies in special populations.
  • Provide early-phase and clinical pharmacology support through the regulatory filing process, including preparation of supporting documents and presentations.
  • Develop and execute studies to validate established and novel clinical biomarkers, including blood and tissue sampling, imaging, electrophysiological measures, wearable devices, and behavioral responses to study biological activity in humans.
  • Provide clinical and scientific expertise to assess internal and external partnership opportunities.
  • Engage with the broader internal and external scientific community in relevant diseases or therapeutic areas through consultations with scientific and academic thought leaders, preparation of posters and publications, and attendance and presentations at conferences.
  • Work with key functions across the company at research sites around the world.
  • Partner with Discovery Sciences to bring a clinical perspective into early target identification and validation and execute clinical studies evaluating the relevance of potential targets to human disease.
  • Lead early clinical development strategy for novel therapeutic programs from the preclinical stage through Phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic studies, Phase 2 proof-of-concept studies, and preparation for Phase 3 clinical trials.
  • Develop biomarker strategies through cross-functional teams, advancing therapeutics from first-in-human studies through clinical proof of concept, including experimental medicine studies to establish or validate biomarker platforms.
  • Develop and execute clinical pharmacology strategies supporting later development stages through worldwide regulatory applications.
Desired Qualifications
  • Experience as an academic faculty member is preferred.
  • Prior experience in the pharmaceutical industry is helpful but not required.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion, up 5% year over year.
  • INTerpath-001 met RFS and DMFS endpoints on August 19, 2026.
  • Merck will present data and pursue filings, expanding intismeran into more tumors.

What critics are saying

  • Keytruda patents start expiring in 2028, exposing Merck to biosimilar erosion.
  • Gardasil layoffs in North Carolina began May 2026, signaling demand weakness and cost pressure.
  • If intismeran disappoints beyond melanoma, Merck loses its clearest post-Keytruda replacement.

What makes Merck unique

  • Keytruda generated $8.37 billion in Q2 2026, powering Merck’s oncology scale.
  • Merck’s August 19, 2026 intismeran win validates individualized mRNA oncology manufacturing.
  • Merck split Human Health on February 23, 2026, sharpening oncology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.